Filing Details

Accession Number:
0001062993-21-008244
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-03 17:05:47
Reporting Period:
2021-09-01
Accepted Time:
2021-09-03 17:05:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
12208 Bio-Rad Laboratories Inc. BIO BIOB Laboratory Analytical Instruments (3826) 941381833
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1485088 J. Andrew Last C/O Bio-Rad Laboratories, Inc.
1000 Alfred Nobel Drive
Hercules CA 94547
Evp, Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Bio-Rad A Common Stock Acquisiton 2021-09-01 2,000 $299.24 3,282 No 4 M Direct
Bio-Rad A Common Stock Disposition 2021-09-01 750 $812.27 2,532 No 4 S Direct
Bio-Rad A Common Stock Disposition 2021-09-01 651 $813.15 1,881 No 4 S Direct
Bio-Rad A Common Stock Disposition 2021-09-01 599 $814.09 1,282 No 4 S Direct
Bio-Rad A Common Stock Acquisiton 2021-09-02 902 $0.00 2,184 No 4 M Direct
Bio-Rad A Common Stock Disposition 2021-09-02 448 $825.77 1,736 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Bio-Rad A Common Stock Restricted Stock Units Acquisiton 2021-09-01 2,532 $0.00 2,532 $0.00
Bio-Rad A Common Stock Non-Qualified Stock Option (right to buy) Acquisiton 2021-09-01 2,532 $0.00 2,532 $814.95
Bio-Rad A Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-09-01 2,000 $0.00 2,000 $299.24
Bio-Rad A Common Stock Restricted Stock Units Disposition 2021-09-02 902 $0.00 902 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,532 No 4 A Direct
2,532 2031-09-01 No 4 A Direct
3,000 2029-04-29 No 4 M Direct
2,708 No 4 M Direct
Footnotes
  1. Includes 13.9278 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.70 to $812.69, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.71 to $813.34, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.02 to $814.11, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. Shares of Class A common stock acquired on the vesting of restricted stock units.
  6. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  7. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
  8. The stock option vests over four years at 25% per year on the yearly anniversary date of the grant.
  9. The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2020, which was the first anniversary of the date on which the option was granted.
  10. On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.